The CTSA program is designed to strengthen and support the entire spectrum of translational research from scientific discovery to improved patient care.
Through a Clinical and Translational Science Awards (CTSA) Program-supported community mentorship program, a neurologist strengthens her translational science skills by increasing her engagement with an underserved population.
Through NCATS’ new Trial Innovation Network, Clinical and Translational Science Awards (CTSA) Program-supported investigators are working collaboratively — including with the CTSA Program Trial Innovation Centers (TICs) and Recruitment Innovation Center (RIC), as well as with other NIH Institutes and Centers — to tackle inefficiencies in clinical trials. The Trial Innovation Network also is designed to be a national laboratory to study, understand and innovate the processes for conducting multisite studies so that more treatments can reach more patients more quickly.
Cell biologist Shawn Hingtgen, Ph.D., is convinced that stem cells can effectively treat brain cancer. Using the support he garnered through NCATS’ Clinical and Translational Science Awards (CTSA) Program mentored career development program, he has collaborated with neurosurgeons, oncologists, stem cell experts, drug development specialists and others to create a potential therapy for glioblastoma multiforme, a deadly type of brain cancer.
Anandi Krishnan, Ph.D., a Stanford University blood/thrombosis researcher, took advantage of an NCATS’ CTSA Program re-entry award in 2016 that allowed her to return to her research career after a leave of absence to care for her child. She now studies a group of rare blood cancers to identify genetic signatures and compiles data to provide a better understanding of the diseases.
CTSA Program hub at UF (funded by NIH) helps bridge the gap between clinician and clinician-scientist, allowing ER physician Dr. Guirgis to create a study for sepsis patients. This team science approach helps prepare clinician-scientists to better address today’s complex research challenges.
Three North Carolina Clinical and Translational Science Awards Program hubs recently collaborated to create a platform for sharing regulatory expertise. Regulatory Guidance for Academic Research of Drugs and Devices features a best practices website to help researchers better navigate the complex regulatory environment in translational science.
Investigators leading the Clinical and Translational Science Awards Program good clinical practice (GCP) standards initiative recently published three papers in the Journal of Clinical and Translational Science. GCP incorporates established ethical and scientific quality standards for the design, conduct, recording and reporting of clinical research involving the participation of human subjects.
CTSA Program hubs at Northwestern University, Ohio State University, and Indiana University utilize collaborations.
An unprecedented trans-NCATS collaboration enables the rapid advancement of a rare lung disease therapy to human trials. aPAP is a rare lung disease with a difficult treatment. With this collaboration, Dr. Trapnell is optimistic that a potentially life-changing treatment is one step closer to benefitting patients.